Publications by authors named "D S Fomina"
Introduction: Currently, limited data are available on long-term use of dupilumab to treat atopic dermatitis (AD) in a multinational real-world setting. The aim of this analysis was to report the interim 1-year data for patients with AD enrolled in the GLOBOSTAD registry, including treatment patterns, dupilumab effectiveness and safety, and healthcare burden.
Methods: GLOBOSTAD is an ongoing, 5-year, multinational, prospective, observational study of adult/adolescent (aged ≥ 12 years at baseline) patients with AD who initiated dupilumab in real-world settings according to their local country-specific prescribing guidelines.
Article Synopsis
- CRUSE® is an app designed for people with chronic spontaneous urticaria (CSU) to track their symptoms using visual analogue scales (VASs), aiming to assess the app's effectiveness in measuring disease activity.
- A study analyzed three VASs related to CSU impact on daily life, including one specifically for the severity of urticaria, one for productivity, and a general health measure (EQ-5D), using data from nearly 6,000 patients over many days.
- The results showed that the CRUSE® app's VASs demonstrate strong validity and reliability, with the "VAS urticaria" being most effective in capturing symptom changes, while the minimal important difference (MID) values indicated meaningful changes
Article Synopsis
- Current treatment recommendations for atopic dermatitis (AD) may not adequately address patients' needs and goals, prompting the development of new strategies for management.
- An international team of dermatology experts created the Aiming High in Eczema/Atopic Dermatitis (AHEAD) recommendations, incorporating patient input and utilizing a modified voting process to achieve consensus on treatment targets.
- The AHEAD approach emphasizes shared decision-making with patients selecting troublesome symptoms while clinicians assess severity; it aims for minimal disease activity as a goal, achieving significant agreement among experts on the proposed guidelines.
Background: There is limited insight into the current disease burden and everyday clinical management of moderate-to- severe AD in Poland, Czechia, Russia, and Turkiye. Therefore, this study aimed to get information-driven insights regarding the current disease burden and clinical management of patients with moderate-to-severe AD with common and differentiating aspects of the patient journey and establish a consensus.
Methods: In this modified 2-round Delphi panel, 133 questions were asked in total to 27 dermatologists.